InvestorsHub Logo
Followers 4
Posts 73
Boards Moderated 0
Alias Born 05/09/2011

Re: None

Wednesday, 03/20/2019 2:16:24 AM

Wednesday, March 20, 2019 2:16:24 AM

Post# of 777
Incase anyone missed this PR.

https://www.prnewswire.com/news-releases/sierra-oncology-announces-late-breaking-oral-and-poster-presentations-at-aacr-2019-for-sra737-and-sra141-preclinical-data-300803591.html

Excerpt:

VANCOUVER, Feb. 27, 2019 /PRNewswire/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and oncology, today announced that an abstract reporting preclinical data for SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in combination with immunotherapy, has been selected for a late-breaking oral presentation at the American Association of Cancer Research (AACR) Annual Meeting 2019, to be held in Atlanta, Georgia from [color=red]March 29 to April 3.